Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Prochlorperazine maleate
Drug ID BADD_D01850
Description Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors.[L6637] Prochlorperazine was first developed in the 1950s [L6643] and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.[L6640]
Indications and Usage Indicated for the symptomatic treatment of severe nausea and vomiting.[label] Indicated for the management of manifestations of psychotic disorders, such as schizophrenia and generalized non-psychotic anxiety. The use of prochlorperazine for the management of generalized non-psychotic anxiety is typically not a first-line therapy and should be limited to doses of less than 20 mg per day or for shorter than 12 weeks.[label,L6634] Off-label uses include use in emergency settings for adult and pediatric migraines. The American Headache Society recommends the use of prochlorperazine as the first-line medication in this setting. In pediatric migraines, a non-steroidal anti-inflammatory agent is often used in combination with dopamine antagonist.[L6637]
Marketing Status approved; vet_approved
ATC Code N05AB04
DrugBank ID DB00433
KEGG ID D00479
MeSH ID D011346
PubChem ID 5281032
TTD Drug ID D0B2UZ
NDC Product Code 38779-0180; 51655-330; 63187-502; 55154-4342; 43063-742; 60219-2038; 63187-251; 70954-688; 70954-689; 68462-889; 70518-1620; 70710-1667; 60219-2039; 67296-0238; 70771-1697; 70771-1698; 46204-0106; 42708-103; 71335-0952; 42291-729; 50090-2839; 50268-684; 69575-4020; 50268-685; 68462-890; 68788-7628; 70710-1668; 42291-728; 59746-113; 59746-115
UNII I1T8O1JTL6
Synonyms Prochlorperazine | Prochlorperazine Edisylate Salt | Edisylate Salt, Prochlorperazine | Salt, Prochlorperazine Edisylate | Prochlorperazine Edisylate | Edisylate, Prochlorperazine | Prochlorperazine Maleate | Maleate, Prochlorperazine | Compazine
Chemical Information
Molecular Formula C28H32ClN3O8S
CAS Registry Number 84-02-6
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyrexia08.05.02.003--
Retinal pigmentation06.09.03.008--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tardive dyskinesia17.01.02.012--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tremor17.01.06.002--
Urinary retention20.02.02.011--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred06.02.06.007; 17.17.01.010--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Brain oedema17.07.02.003; 12.01.10.010--
Electrocardiogram change13.14.05.014--Not Available
Lactation disorder21.05.02.004; 18.06.02.003--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Epinephrine abnormal13.10.01.003--Not Available
Psychotic disorder19.03.01.002--
Pigmentation disorder23.05.03.001--Not Available
The 3th Page    First    Pre   3    Total 3 Pages